AtaiBeckley (ATAI) Assets Average (2021 - 2026)
AtaiBeckley (ATAI) posted quarterly Assets Average of $278.8 million for Q1 2026.
Analysis
AtaiBeckley (ATAI) Assets Average (2021 - 2026) Analysis & Trends
AtaiBeckley's Assets Average history runs 1 years deep, the most recent figure standing at $278.8 million for Q1 2026.
- Quarterly Assets Average fell 71.08% year-over-year to $81.3 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $81.3 million (down 71.08% YoY) and the FY2024 annual result came in at $226.4 million, down 24.39% from the prior year.
- Assets Average fell to $81.3 million in Q1 2025 per ATAI's latest filing, from $242.4 million in the prior quarter.
- Over five years, Assets Average peaked at $324.0 million in Q4 2022 and troughed at $885000.0 in Q2 2021.
- A 5-year average of $173.5 million and a median of $254.8 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2025: Assets Average surged 11377.83% in 2022, then slumped 71.08% in 2025.
- Over 5 years, Assets Average stood at $2.8 million in 2021, then soared by 11377.83% to $324.0 million in 2022, then retreated by 7.15% to $300.8 million in 2023, then retreated by 19.41% to $242.4 million in 2024, then sank by 66.45% to $81.3 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $81.3 million, $242.4 million, and $281.3 million for Q1 2025, Q2 2024, and Q1 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | AtaiBeckley | 1.61 Bn | 1.61 Bn | - | 214.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 264.84 Mn |
| Mar 31, 2026 | 278.80 Mn |
| Sep 30, 2025 | 214.51 Mn |
| Jun 30, 2025 | 192.49 Mn |
| Mar 31, 2025 | 177.59 Mn |
| Dec 31, 2024 | 178.45 Mn |
| Sep 30, 2024 | 206.65 Mn |
| Jun 30, 2024 | 242.45 Mn |
| Mar 31, 2024 | 281.30 Mn |
| Dec 31, 2023 | 300.85 Mn |
| Sep 30, 2023 | 280.91 Mn |
| Jun 30, 2023 | 267.16 Mn |
| Mar 31, 2023 | 293.08 Mn |
| Mar 31, 2022 | 194.25 Mn |
| Dec 31, 2021 | 2.82 Mn |
| Sep 30, 2021 | 885,000.00 |
| Jun 30, 2021 | 885,000.00 |
| Mar 31, 2021 | 6.60 Mn |